Japanese drugmaker Daiichi Sankyo Co. has applied with the health ministry for approval of a new coronavirus vaccine, aiming to be the first in the nation to put a domestically developed messenger RNA vaccine into use.The same type of vaccine developed by Pfizer Inc. and Moderna Inc., both of the United States, has already been in use in Japan. Daiichi Sankyo's is tailored for previously dominant variants and intended for third jabs.Daiichi Sankyo announced its application for its mRNA vaccine's manufacture and sale on Friday, with plans to put it into use by the end of this year.With Japan…READ FULL ARTICLE
